Novartis announced that it entered into a definitive agreement to acquire all of the outstanding share capital of the UK-based ocular gene therapy company Gyroscope Therapeutics. Also Read: FDA Approves Otezla (Apremilast) For the Treatment of Adult Patients With Plaque Psoriasis, Regardless of Severity Level Geographic atrophy (GA) is an advanced form of dry age-related… Continue reading Novartis to acquire Gyroscope Therapeutics, adding a one-time gene therapy that could transform care for geographic atrophy, a leading cause of blindness